CA3109610A1 - Heterocyclic compound - Google Patents
Heterocyclic compound Download PDFInfo
- Publication number
- CA3109610A1 CA3109610A1 CA3109610A CA3109610A CA3109610A1 CA 3109610 A1 CA3109610 A1 CA 3109610A1 CA 3109610 A CA3109610 A CA 3109610A CA 3109610 A CA3109610 A CA 3109610A CA 3109610 A1 CA3109610 A1 CA 3109610A1
- Authority
- CA
- Canada
- Prior art keywords
- mhz
- nmr1
- ring
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018-167488 | 2018-09-07 | ||
| JP2018167488 | 2018-09-07 | ||
| PCT/JP2019/035233 WO2020050409A1 (en) | 2018-09-07 | 2019-09-06 | Heterocyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3109610A1 true CA3109610A1 (en) | 2020-03-12 |
Family
ID=68063002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3109610A Pending CA3109610A1 (en) | 2018-09-07 | 2019-09-06 | Heterocyclic compound |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11932657B2 (https=) |
| EP (1) | EP3847176A1 (https=) |
| JP (1) | JP7448527B2 (https=) |
| KR (1) | KR102810086B1 (https=) |
| CN (1) | CN112654627A (https=) |
| AU (2) | AU2019335968B2 (https=) |
| CA (1) | CA3109610A1 (https=) |
| EA (1) | EA202190654A1 (https=) |
| IL (1) | IL280821B2 (https=) |
| SG (1) | SG11202101963XA (https=) |
| TW (1) | TWI854995B (https=) |
| WO (1) | WO2020050409A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7448527B2 (ja) | 2018-09-07 | 2024-03-12 | 大塚製薬株式会社 | ヘテロ環式化合物 |
| IL291322B2 (en) | 2019-12-09 | 2026-02-01 | Otsuka Pharma Co Ltd | Acrylamide compounds |
| US20230279000A1 (en) | 2020-02-26 | 2023-09-07 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN115215720B (zh) * | 2021-04-19 | 2023-08-22 | 中国科学院化学研究所 | 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用 |
| WO2022228399A1 (zh) * | 2021-04-27 | 2022-11-03 | 山东轩竹医药科技有限公司 | 三并环类usp1抑制剂及其用途 |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| KR20240054994A (ko) * | 2021-09-02 | 2024-04-26 | 재규어 테라퓨틱스 피티이 리미티드 | AhR 시그널링의 조절에 유용한 화합물 |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| JP7527515B1 (ja) * | 2022-10-29 | 2024-08-02 | 松本油脂製薬株式会社 | 弾性繊維用処理剤及びその利用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| CN103313989B (zh) | 2010-12-16 | 2016-05-04 | 霍夫曼-拉罗奇有限公司 | 三环pi3k抑制剂化合物和使用方法 |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| DK3312270T3 (da) | 2015-06-16 | 2020-10-12 | Univ Kyoto | Fremgangsmåde til fremstilling af plader med høj ydeevne |
| WO2018195397A2 (en) * | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| WO2019167973A1 (en) | 2018-03-01 | 2019-09-06 | Kyoto University | Cell cycle progression inhibitor |
| JP7448527B2 (ja) | 2018-09-07 | 2024-03-12 | 大塚製薬株式会社 | ヘテロ環式化合物 |
| IL291322B2 (en) | 2019-12-09 | 2026-02-01 | Otsuka Pharma Co Ltd | Acrylamide compounds |
| JP2022188761A (ja) | 2021-06-09 | 2022-12-21 | 大塚製薬株式会社 | 窒素原子含有複素環化合物を用いる血小板産生方法 |
-
2019
- 2019-09-06 JP JP2021512830A patent/JP7448527B2/ja active Active
- 2019-09-06 CN CN201980058108.7A patent/CN112654627A/zh active Pending
- 2019-09-06 EP EP19773956.8A patent/EP3847176A1/en active Pending
- 2019-09-06 KR KR1020217009658A patent/KR102810086B1/ko active Active
- 2019-09-06 SG SG11202101963XA patent/SG11202101963XA/en unknown
- 2019-09-06 EA EA202190654A patent/EA202190654A1/ru unknown
- 2019-09-06 US US17/271,479 patent/US11932657B2/en active Active
- 2019-09-06 TW TW108132216A patent/TWI854995B/zh active
- 2019-09-06 IL IL280821A patent/IL280821B2/en unknown
- 2019-09-06 WO PCT/JP2019/035233 patent/WO2020050409A1/en not_active Ceased
- 2019-09-06 CA CA3109610A patent/CA3109610A1/en active Pending
- 2019-09-06 AU AU2019335968A patent/AU2019335968B2/en active Active
-
2024
- 2024-01-18 US US18/416,261 patent/US20240208999A1/en active Pending
- 2024-06-04 AU AU2024203760A patent/AU2024203760A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019335968A1 (en) | 2021-05-06 |
| US20210340157A1 (en) | 2021-11-04 |
| CN112654627A (zh) | 2021-04-13 |
| WO2020050409A1 (en) | 2020-03-12 |
| IL280821B1 (en) | 2024-10-01 |
| EA202190654A1 (ru) | 2021-05-27 |
| KR102810086B1 (ko) | 2025-05-21 |
| IL280821B2 (en) | 2025-02-01 |
| US11932657B2 (en) | 2024-03-19 |
| SG11202101963XA (en) | 2021-03-30 |
| NZ774547A (en) | 2025-10-31 |
| EP3847176A1 (en) | 2021-07-14 |
| US20240208999A1 (en) | 2024-06-27 |
| TW202035423A (zh) | 2020-10-01 |
| JP7448527B2 (ja) | 2024-03-12 |
| TWI854995B (zh) | 2024-09-11 |
| JP2021536482A (ja) | 2021-12-27 |
| AU2024203760A1 (en) | 2024-06-20 |
| KR20210056373A (ko) | 2021-05-18 |
| IL280821A (en) | 2021-04-29 |
| AU2019335968B2 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3109610A1 (en) | Heterocyclic compound | |
| CN101835764B (zh) | 唑甲酰胺化合物或其盐 | |
| JP6445574B2 (ja) | ブロモドメイン阻害剤 | |
| AU2005322920B2 (en) | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | |
| CA2793856C (en) | Tetrahydrobenzothiophene compound | |
| TWI440639B (zh) | 作為ｔｒｐｖ１調節劑之四氫-嘧啶并氮呯類 | |
| JP6452703B2 (ja) | Ｗｎｔ経路モジュレーター | |
| SK12712002A3 (sk) | Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz | |
| CA2928541A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| TWI836960B (zh) | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 | |
| JP2017525668A (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| CA2839699A1 (en) | Trpm8 antagonists and their use in treatments | |
| JP2007522233A (ja) | バニロイド受容体リガンド及び治療におけるそれらの使用 | |
| TW201406736A (zh) | 新穎的醯胺衍生物或其鹽 | |
| JP2007145828A (ja) | 医薬組成物 | |
| WO2010102154A2 (en) | Biaryl oxyacetic acid compounds | |
| CN112469714B (zh) | 作为端锚聚合酶抑制剂的1,2,4-三唑衍生物 | |
| CA3155466A1 (en) | Acrylamide compounds | |
| EA046483B1 (ru) | Гетероциклическое соединение | |
| HK40048052A (zh) | 杂环化合物 | |
| CN112480018B (zh) | 一种trpv3小分子变构抑制剂及其制备方法 | |
| CN101171015A (zh) | 作为离子通道配体的酰胺衍生物、药物组合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240829 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240829 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240829 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241108 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250722 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250722 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260224 |